Abstracts Archive - Page 9 of 2607 - ACR Meeting Abstracts

Abstract Number: 0059 • ACR Convergence 2025
Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
Ryan D. Stultz¹, Payton Hermanson², Noelle Mullin³, Simeon Ramsey³ and Christian Lood², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²University of Washington, Seattle, WA, ³Pfizer Inc., Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that disproportionately affects females over males (3:1). Although sex-based immune differences have been documented, particularly…
Abstract Number: 0056 • ACR Convergence 2025
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Maripat Corr¹, Grace Hsueh², Aaron place², David Lucas² and NANCY LANE³, ¹ucsd, San Diego, CA, ²ANI Pharmaceuticals, Inc., Baudette, MN, ³University of California at Davis, School of Medicine, Sacramento, CA
Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
Abstract Number: 0031 • ACR Convergence 2025
Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Alba Boix-Amoros³, Adam Cantor⁴, Jose Scher⁵ and Jose Clemente¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU Langone Health, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴Icahn School of Medicine, New York, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. The sharp increase in prevalence of these disorders over recent decades suggests that factors…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Peter Taylor¹, Jason Carlson², Shirley Vu², Signe Fransen³, Diana Abdueva⁴ and Jeffrey Curtis⁵, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual, sf, CA, ⁴Aqtual, Hayward, CA, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
Abstract Number: 0049 • ACR Convergence 2025
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago
Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…
Abstract Number: 0019 • ACR Convergence 2025
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
Alejandro Gómez Gómez¹, Héctor Corominas², Rosario Garcia Vicuña³, Mercedes Freire González⁴, Sheila Melchor-Díaz⁵, Paloma Vela Casasempere⁶, Paula Estrada-Alarcón⁷, Jose Luis Tandaipan⁸, Monica Fernandez Castro⁹, Sara Maria Rojas Herrera¹⁰, Marina Rodríguez López¹¹, Beatriz Paredes-Romero¹², Santiago Muñoz¹³, Marta López¹⁴, Ignacio Braña¹⁵, Gema Bonilla¹⁶, Raúl Menor Almagro¹⁷, Sara Manrique-Arija¹⁸, Mª Angeles Blazquez Cañamero¹⁹, Lilian López-Núñez²⁰, Carles Galisteo Veiga²¹, Juan José Alegre-Sancho²², Jose Rosas Gómez de Salazar²³, Jose Javier Pérez Venegas²⁴, Judit Font-Urgelles²⁵, José Andrés Román Ivorra²⁶, José Miguel Sequí-Sabater²⁷, Rafaela Ortega-Castro²⁸, Clara Moriano²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Javier Narváez³², Rafael Cáliz-Cáliz³³, Javier Martínez-Ferrin³⁴, Lara Sánchez Bilbao³⁵, Belén Serrano-Benavente³⁶, Natalia Boix- Martí³⁷, Ares Selles-Rius³⁸, Maribel Pérez³⁹, Juan Cañete⁴⁰, Núria Palau Balaña³⁸, Damiana Alvarez Errico³⁹, Yolanda Guillén⁴¹, Juan Ángel Patiño Galindo⁴¹, Antonio Julià¹, Sara Marsal Barril⁴² and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Barcelona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ⁵Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁶Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ⁷Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁸Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹¹Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹³Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁴Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ¹⁸Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁹Hospital Ramon y Cajal, Madrid, Spain, ²⁰Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²¹Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²²Hospital Universitario Doctor Peset, Valencia, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁷Hospital Universitario La Fe (Valencia), Valencia, Spain, ²⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²⁹Hospital León, LEON, Castilla y Leon, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Hospital Universitario de Bellvitge, Barcelona, Spain, ³³Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁴Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³⁶Hospital Gregorio Marañon, Madrid, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ³⁹IMIDomics, Barcelona, Barcelona, Spain, ⁴⁰Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Spain, ⁴²Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…
Abstract Number: 0061 • ACR Convergence 2025
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Shinjiro Kaieda¹, Suzuna Sugi¹, Takuma Koga², Takashi Kinoshita¹ and Tomoaki Hoshino¹, ¹Kurume university School of Medicine, Kurume, Japan, ²Kurume Universty School of Medicine, Kurume, Japan
Background/Purpose: IL-22 is a key cytokine involved in modulating tissue responses during inflammation and is markedly upregulated in inflammatory diseases, such as psoriasis, inflammatory bowel…
Abstract Number: 0094 • ACR Convergence 2025
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Sagrario Corrales¹, Laura muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera⁴, Lourdes Ladehesa⁵, Pilar Font⁶, Ismael Sanchez-Pareja¹, M Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez⁸, Christian Merlo⁹, MARIA ANGELES AGUIRRE ZAMORANO¹, Tomás Cerdó¹, Nuria Barbarroja¹⁰, Marta Alarcon-Riquelme¹¹, Alejandro Escudero Contreras⁴, Carlos Pérez Sánchez¹² and Chary López pedrera¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁸Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0095 • ACR Convergence 2025
Effect of JAK Inhibitors on Osteoblast Differentiation
Toshihiro Tanioka¹ and Takeo Isozaki², ¹Graduate School of Pharmacy, Showa Medical University, Shinagawa-ku,Tokyo, Tokyo, Japan, ²Graduate School of Pharmacy, Showa Medical University, Tokyo, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…
Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 0042 • ACR Convergence 2025
Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, liqun Diao⁵, Igor Jurisica⁶, Vinod Chandran⁷ and Lihi Eder⁸, ¹Institute of Medical Science, University of Toronto, Toronto, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women’s College Research Institute, Toronto, Canada, ⁴Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, ⁶University Health Network, Toronto, Canada, ⁷Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].